Additional studies showing combination NLRP3 inhibition-anti-PD-1 antibody therapy to generate a more effective anti-tumor immune response over anti-PD-1 monotherapy in the autochthonous BRAFV600E melanoma model further support the importance of this tumor-intrinsic pathway in mediating resistance to checkpoint inhibitor immunotherapy. Here, NLRP3 is linked to melanoma.